{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:12:37Z","timestamp":1769512357003,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32401263"],"award-info":[{"award-number":["32401263"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007957","name":"Chongqing Municipal Education Commission","doi-asserted-by":"publisher","award":["KJQN202200468"],"award-info":[{"award-number":["KJQN202200468"]}],"id":[{"id":"10.13039\/501100007957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.intimp.2025.115435","type":"journal-article","created":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T17:22:04Z","timestamp":1757265724000},"page":"115435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["IFN\u03b12b in combination with oncolytic adenovirus enhances antitumor activity against melanoma"],"prefix":"10.1016","volume":"165","author":[{"given":"Qingman","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongjing","family":"hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"She","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115435_bb0005","first-page":"367","article-title":"Harrington melanoma: diagnosis and treatment","volume":"110","author":"Lauters","year":"2024","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.intimp.2025.115435_bb0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.intimp.2025.115435_bb0015","doi-asserted-by":"crossref","unstructured":"L. Yu, F. Yan, J. Qi, L. Wang, M. Zhou and P. Yin Burden of melanoma in China and its provinces from 1990 To 2021: an analysis for the global burden of disease study 2021. Front. Public Health 2024;12:1486617.","DOI":"10.3389\/fpubh.2024.1486617"},{"key":"10.1016\/j.intimp.2025.115435_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.107969","article-title":"Perioperative therapy of melanoma: adjuvant or neoadjuvant treatment","volume":"50","author":"Rutkowski","year":"2024","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.intimp.2025.115435_bb0025","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1097\/JS9.0000000000001479","article-title":"Tian comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, and large-sample informatics study","volume":"110","author":"Guo","year":"2024","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.intimp.2025.115435_bb0030","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1470-2045(18)30106-2","article-title":"Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"19","author":"Maio","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2025.115435_bb0035","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.18.01219","article-title":"Longer follow-up confirms relapse-free survival benefit with adjuvant Dabrafenib plus Trametinib in patients with resected BRAF V600-mutant stage III melanoma","volume":"36","author":"Hauschild","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115435_bb0040","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115435_bb0045","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115435_bb0050","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115435_bb0055","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.critrevonc.2012.07.004","article-title":"Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review","volume":"85","author":"Ascierto","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.intimp.2025.115435_bb0060","first-page":"2489","article-title":"Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons","volume":"58","author":"Pfeffer","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2025.115435_bb0065","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/annonc\/mdi125","article-title":"Interferon-alpha as maintenance therapy in patients with multiple myeloma","volume":"16","author":"Schaar","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2025.115435_bb0070","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cytogfr.2015.01.001","article-title":"Corrales new perspectives on type I IFNs in cancer","volume":"26","author":"Gajewski","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.intimp.2025.115435_bb0075","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12967-022-03450-3","article-title":"Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males","volume":"20","author":"Saad","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2025.115435_bb0080","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnci\/djq009","article-title":"Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis","volume":"102","author":"Mocellin","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.intimp.2025.115435_bb0085","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1200\/JCO.2004.10.045","article-title":"Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma","volume":"22","author":"Alatrash","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115435_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111647","article-title":"Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8(+) T cell exhaustion and curtails anti-PD-1 efficacy","volume":"41","author":"Chen","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2025.115435_bb0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2016.12.011","article-title":"Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients","volume":"73","author":"Wistuba-Hamprecht","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2025.115435_bb0100","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.2008.20.2069","volume":"27","author":"Bottomley","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115435_bb0105","first-page":"122","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy. Trends","volume":"9","author":"Ma","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2025.115435_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.775761","article-title":"Improving immunotherapy efficacy in soft-tissue sarcomas: A biomarker driven and Histotype tailored review","volume":"12","author":"Roulleaux Dugage","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115435_bb0115","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","article-title":"Nelson oncolytic viruses as engineering platforms for combination immunotherapy","volume":"18","author":"Twumasi-Boateng","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2025.115435_bb0120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.115435_bb0125","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41392-024-01824-1","article-title":"Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects","volume":"9","author":"Fu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115435_bb0130","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1021\/acs.nanolett.9b00145","article-title":"Genetically engineered cell membrane Nanovesicles for oncolytic adenovirus delivery: A versatile platform for Cancer Virotherapy","volume":"19","author":"Lv","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.intimp.2025.115435_bb0135","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.1039\/D1BM00928A","article-title":"Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy","volume":"9","author":"Lv","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.intimp.2025.115435_bb0140","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/bjd\/ljad183","article-title":"Postoperative adjuvant therapy for 120 patients with melanoma, including acral and mucosal subtypes: a multicentre, observational study of 2-year follow-up results","volume":"189","author":"Muto","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2025.115435_bb0145","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(05)17951-3","article-title":"Kefford cutaneous melanoma","volume":"365","author":"Thompson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2025.115435_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202202710","article-title":"Oxidative stress amplifiers as immunogenic cell death Nanoinducers disrupting mitochondrial redox homeostasis for Cancer immunotherapy","volume":"12","author":"Wan","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.intimp.2025.115435_bb0155","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ymthe.2021.09.015","article-title":"High-dose VitC plus oncolytic adenoviruses enhance immunogenic tumor cell death and reprogram tumor immune microenvironment","volume":"30","author":"Ma","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2025.115435_bb0160","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Zitvogel immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115435_bb0165","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/s41467-024-46685-y","article-title":"Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors","volume":"15","author":"L\u00f3pez","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115435_bb0170","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.immuni.2013.03.003","article-title":"Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells","volume":"38","author":"Ma","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115435_bb0175","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.ccell.2023.06.008","article-title":"A distinct stimulatory cDC1 subpopulation amplifies CD8(+) T cell responses in tumors for protective anti-cancer immunity","volume":"41","author":"Meiser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115435_bb0180","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.immuni.2023.06.003","article-title":"CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8(+) T cell antitumor immunity","volume":"56","author":"Moreno Ayala","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115435_bb0185","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41392-024-01838-9","article-title":"Targeting BCL9\/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115435_bb0190","first-page":"784","article-title":"Reis e Sousa the role of type 1 conventional dendritic cells in Cancer immunity. Trends","volume":"4","author":"B\u00f6ttcher","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2025.115435_bb0195","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","article-title":"PD-1 blockade expands Intratumoral memory T cells","volume":"4","author":"Ribas","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2025.115435_bb0200","doi-asserted-by":"crossref","first-page":"e1512","DOI":"10.1212\/WNL.0000000000200137","article-title":"Association of Emerging \u03b2-amyloid and tau pathology with early cognitive changes in clinically Normal older adults","volume":"98","author":"Farrell","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2025.115435_bb0205","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.20.01098","volume":"38","author":"El-Jawahri","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115435_bb0210","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.preghy.2021.08.114","article-title":"Miralles Mart\u00ednez cerebral hemodynamics and vasoconstriction in preeclampsia: from diagnosis to resolution","volume":"26","author":"Mart\u00ednez-Mart\u00ednez","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.intimp.2025.115435_bb0215","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy promotes Intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.115435_bb0220","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/1878-0261.13603","article-title":"STING activator 2\u20323\u2019-cGAMP enhanced HSV-1-based oncolytic viral therapy","volume":"18","author":"Sibal","year":"2024","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.intimp.2025.115435_bb0225","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12943-024-02140-6","article-title":"Artificial intelligence alphafold model for molecular biology and drug discovery: a machine-learning-driven informatics investigation","volume":"23","author":"Guo","year":"2024","journal-title":"Mol. Cancer"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925014262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925014262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:23:14Z","timestamp":1763047394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925014262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":45,"alternative-id":["S1567576925014262"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115435","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IFN\u03b12b in combination with oncolytic adenovirus enhances antitumor activity against melanoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115435"}}